163 related articles for article (PubMed ID: 35533440)
1. Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs.
Wu T; Rabi SA; Michaud WA; Becerra D; Gilpin SE; Mino-Kenudson M; Ott HC
Biomaterials; 2022 Jun; 285():121509. PubMed ID: 35533440
[TBL] [Abstract][Full Text] [Related]
2. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
3. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
6. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
7. Protease inhibitors targeting coronavirus and filovirus entry.
Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
[TBL] [Abstract][Full Text] [Related]
8. Human airway lineages derived from pluripotent stem cells reveal the epithelial responses to SARS-CoV-2 infection.
Wang R; Hume AJ; Beermann ML; Simone-Roach C; Lindstrom-Vautrin J; Le Suer J; Huang J; Olejnik J; Villacorta-Martin C; Bullitt E; Hinds A; Ghaedi M; Rollins S; Werder RB; Abo KM; Wilson AA; Mühlberger E; Kotton DN; Hawkins FJ
Am J Physiol Lung Cell Mol Physiol; 2022 Mar; 322(3):L462-L478. PubMed ID: 35020534
[TBL] [Abstract][Full Text] [Related]
9. Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus.
Ekanger CT; Zhou F; Bohan D; Lotsberg ML; Ramnefjell M; Hoareau L; Røsland GV; Lu N; Aanerud M; Gärtner F; Salminen PR; Bentsen M; Halvorsen T; Ræder H; Akslen LA; Langeland N; Cox R; Maury W; Stuhr LEB; Lorens JB; Engelsen AST
Front Cell Infect Microbiol; 2022; 12():841447. PubMed ID: 35360113
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
11. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
Breining P; Frølund AL; Højen JF; Gunst JD; Staerke NB; Saedder E; Cases-Thomas M; Little P; Nielsen LP; Søgaard OS; Kjolby M
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):204-212. PubMed ID: 33176395
[TBL] [Abstract][Full Text] [Related]
12. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response.
Huang J; Hume AJ; Abo KM; Werder RB; Villacorta-Martin C; Alysandratos KD; Beermann ML; Simone-Roach C; Lindstrom-Vautrin J; Olejnik J; Suder EL; Bullitt E; Hinds A; Sharma A; Bosmann M; Wang R; Hawkins F; Burks EJ; Saeed M; Wilson AA; Mühlberger E; Kotton DN
Cell Stem Cell; 2020 Dec; 27(6):962-973.e7. PubMed ID: 32979316
[TBL] [Abstract][Full Text] [Related]
14. Authentic Modeling of Human Respiratory Virus Infection in Human Pluripotent Stem Cell-Derived Lung Organoids.
Porotto M; Ferren M; Chen YW; Siu Y; Makhsous N; Rima B; Briese T; Greninger AL; Snoeck HW; Moscona A
mBio; 2019 May; 10(3):. PubMed ID: 31064833
[TBL] [Abstract][Full Text] [Related]
15. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection.
Pei R; Feng J; Zhang Y; Sun H; Li L; Yang X; He J; Xiao S; Xiong J; Lin Y; Wen K; Zhou H; Chen J; Rong Z; Chen X
Protein Cell; 2021 Sep; 12(9):717-733. PubMed ID: 33314005
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response.
Huang J; Hume AJ; Abo KM; Werder RB; Villacorta-Martin C; Alysandratos KD; Beermann ML; Simone-Roach C; Lindstrom-Vautrin J; Olejnik J; Suder EL; Bullitt E; Hinds A; Sharma A; Bosmann M; Wang R; Hawkins F; Burks EJ; Saeed M; Wilson AA; Mühlberger E; Kotton DN
bioRxiv; 2020 Aug; ():. PubMed ID: 32637964
[TBL] [Abstract][Full Text] [Related]
17. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
18. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
19. Human Nasal Organoids Model SARS-CoV-2 Upper Respiratory Infection and Recapitulate the Differential Infectivity of Emerging Variants.
Chiu MC; Li C; Liu X; Song W; Wan Z; Yu Y; Huang J; Xiao D; Chu H; Cai JP; To KK; Yuen KY; Zhou J
mBio; 2022 Aug; 13(4):e0194422. PubMed ID: 35938726
[TBL] [Abstract][Full Text] [Related]
20. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
